TLDR
- Moderna stock rose 2.2% in pre-market trading to $193.15 after Nasdaq confirmed it will join the Nasdaq-100 Index on October 9.
- MRNA replaces Warner Bros. Discovery, which is being acquired by Paramount Skydance in an $81 billion deal expected to close October 6.
- The stock is up about 553% year-to-date, pushing Moderna’s market value to roughly $75.4 billion.
- Citi analyst Geoff Meacham downgraded MRNA to Sell, saying the rally has outpaced what the oncology pipeline can support.
- Wall Street holds a Hold consensus rating on MRNA, with the average price target implying 42% downside.
Moderna stock climbed 2.2% in pre-market trading on Friday, touching $193.15. The jump followed Nasdaq’s announcement that Moderna will officially join the Nasdaq-100 Index before markets open on October 9.
The move isn’t about new drug data. It’s about index mechanics.
Moderna is replacing Warner Bros. Discovery in the benchmark. That company is being absorbed into Paramount Skydance through an $81 billion merger. A federal judge recently approved a settlement clearing the path for that deal, which is expected to close on October 6.
Once Moderna’s spot in the index is confirmed, funds that track the Nasdaq-100 will need to buy in. That’s over $800 billion in assets tied to the index, so even a small rebalancing creates real buying pressure.
A Wild Year for MRNA
This has been an extraordinary year for Moderna stock. Shares are up around 553% since January, giving the company a market value near $75.4 billion.
Much of that surge traces back to positive Phase 3 results for intismeran autogene, the personalized melanoma vaccine Moderna developed alongside Merck. The stock has gained roughly 222% since those interim results were first reported.
Moderna is currently trading close to its 52-week high of $208.90. That’s a dramatic turnaround for a company whose stock spent years drifting lower after the pandemic-era vaccine boom faded.
The broader market gave Moderna some room to run too. The S&P 500 added 0.5%, the Dow Jones rose 0.5%, and the Nasdaq gained 0.8% on the day. Peers BioNTech and Pfizer stayed mostly flat, suggesting this move is specific to Moderna rather than a sector-wide swing.
Not Everyone Is Convinced
Not every analyst is on board with the rally. Citi’s Geoff Meacham downgraded Moderna to Sell from Neutral just days before the Nasdaq-100 news broke.
He did raise his price target, moving it to $80 from $60. But the rating itself sends a clear signal: Meacham thinks the stock has run too far, too fast.
His argument centers on math. Citi estimates Moderna would need close to $13 billion in yearly oncology sales to justify a share price near $200. That figure is nearly seven times what the firm currently forecasts for Moderna’s cancer business.
Meacham called those implied sales expectations unrealistic.
Despite the downgrade, buyers stepped back in the very next session. That recovery has carried through to this week’s pre-market activity, pushing the stock higher once again.
Wall Street overall remains split. Twenty analysts have weighed in over the past three months, landing on a Hold consensus for MRNA.
The average price target sits at $110.44. That’s about 42% below where the stock currently trades, a gap wide enough to show just how divided opinion has become.
Moderna also recently created a new Chief Operating Officer role, appointing Juan Andres to the post. The move is meant to help the company scale manufacturing as its oncology pipeline grows.
Investors are now looking ahead to October 24, when Moderna is set to present new data at the ESMO conference. That presentation could become the next catalyst for the stock, one way or another.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
